U.S. to study whether longer Paxlovid course needed to combat reinfections
Reuters
5/18/2022
© Reuters/PFIZER
FILE PHOTO: Pfizer's COVID-19 pill Paxlovid is packaged in Ascoli
By Michael Erman
(Reuters) - The U.S. National Institutes of Health is in talks with Pfizer Inc about studying whether a longer course of the drugmaker's COVID-19 antiviral treatment Paxlovid is needed to prevent reinfections, top U.S. infectious diseases expert Dr. Anthony Fauci said on Wednesday.
-
Ketanji Brown Jackson is officially sworn in as the newest Supreme Court justice
USA TODAY -
U.S. emissions ruling makes climate fight harder: UN
Reuters -
Nightly News: Kids Edition (June 30, 2022)
NBC News -
'As long as it takes': Biden pledges to support Ukraine
MSNBC -
Adm. Stavridis: ‘It’s a very good day for NATO’
MSNBC -
Those denying Hutchinson’s testimony still agree that Trump ‘desperately wanted to go to the Capitol’
MSNBC -
Which Justices Sit On The U.S. Supreme Court?
Newsweek -
Ukrainian troops in U.K. receive training in multiple launch rocket systems
NBC News -
WH economist: We can take practical steps to help U.S. families
MSNBC -
German Chancellor Olaf Scholz says Putin is ready to wage war in Ukraine for "a long time"
CBS News -
Bill Nye: 'Vote for better laws to control climate change'
NBC News -
Beyoncé Joins Snapchat Day Before Paid Subscription Launch
Newsweek -
Putin made a 'big and huge mistake': NATO Secretary General
CNN -
Man left partially paralyzed after injury in police custody
CNN -
New Jersey Governor Signs Budget That Includes $500 Child Tax Credit
Newsweek -
Supreme Court term ends with historic swearing in of Justice Jackson, first Black woman on the high court
MSNBC
-
Ketanji Brown Jackson is officially sworn in as the newest Supreme Court justice Ketanji Brown Jackson has officially been sworn in as the first Black woman justice on the Supreme Court of the United States.
USA TODAY
-
U.S. emissions ruling makes climate fight harder: UN A U.S. Supreme Court ruling on Thursday (June 30) limiting Washington's authority to reduce carbon emissions from power plants is "a setback in our fight against climate change," United Nations spokesman Stephane Dujarric said.
Reuters
-
Nightly News: Kids Edition (June 30, 2022) Can dogs get sunburn? As the summer season gets underway, Dr. John Torres is here to answer your questions. Plus, we meet the newest four-legged member of the Ferguson Fire Department. Our Inspiring Kids series continues: We introduce you to a girl on a mission to help kids find comfort and joy after they were diagnosed with cancer. Kerry Sanders takes us to Normandy, France to spotlight those who found for freedom on D-Day. And more!
NBC News
"We're going to be planning what studies we're going to be doing relatively soon, within the next few days" in order to determine whether or not a longer course is needed, Fauci said during a White House COVID-19 briefing.
Rising COVID-19 cases in the United States are driving up use of therapeutics, with more than 660,000 courses of Paxlovid pills administered in the country so far.
Some patients have reported that COVID symptoms recurred after completing the five-day course of treatment and experiencing improvement, but exactly how many have experienced such a rebound is unclear.
In Pfizer's clinical trial, around 2% of recipients who received the two-drug treatment saw an increase in viral load after completing the standard course, compared with around 1.5% of placebo recipients.
White House COVID-19 response coordinator Dr. Ashish Jha said that data was compiled when Delta was the dominant variant of the coronavirus, and it is unclear whether reinfections are more common with Omicron now predominant.
Jha said that reinfections do not seem to hamper Paxlovid's ability to reduce hospitalizations and deaths from COVID-19.
Pfizer has suggested that a second five-day course of Paxlovid could treat reinfections. The U.S. Food and Drug Administration said there is currently no evidence to support taking a second five-day course or a 10-day course of the pills.
(This story refiles to fix typographical error in third paragraph)
(Reporting by Michael Erman; Editing by Bill Berkrot)
Reuters
